Drug Trial Radar · NCT07203365
RSV Immunogenicity Study in the Elderly (RISE)
Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
75
Actual
Start
Aug 25, 2025
Primary completion
May 31, 2027
Study completion May 31, 2029
Sponsor
- Lead sponsor
- Karin Karin LoréAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Karolinska Institutet
- First posted
- Oct 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Respiratory syncytial virus (RSV) is a common cause of respiratory tract infections leading to hospitalizations in infants and in elderly. Arexvy is an approved vaccine for the prevention of RSV infection, however, data on its efficacy in individuals aged 80 years and older remain limited. This study aims to evaluate potential differences in immune responses to Arexvy vaccination between adults aged ≥80 years and those aged 60-65 years.
Conditions
- RSV Immunisation
Interventions
This study examines immune response differences Arexvy between individuals aged 80+ and adults aged 60-65Biological
The RSV vaccine (Arexvy) has demonstrated efficacy against LRTD over three RSV seasons in individuals aged 60 and older, with an acceptable safety and reactogenicity profile. However, data on vaccine responses in individuals aged 80 and older, including frail individuals, remains limited. This population is particularly affected by severe RSV infections, highlighting the need for further investigation to address these gaps.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary endpoint:Time frame: Day 31
- Primary objectiveTime frame: Day 31
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Familjeläkarna SÄBO
Saltsjöbaden, Sweden
Akademiskt specialistcentrum Studieenheten
Stockholm, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.